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Abstract
Background: Explaining parasite virulence (harm to the host) represents a major challenge for
evolutionary and biomedical scientists alike. Most theoretical models of virulence evolution assume
that virulence arises as a direct consequence of host exploitation, the process whereby parasites
convert host resources into transmission opportunities. However, infection-induced disease can
be immune-mediated (immunopathology). Little is known about how immunopathology affects
parasite fitness, or how it will affect the evolution of parasite virulence. Here we studied the effects
of immunopathology on infection-induced host mortality rate and lifetime transmission potential –
key components of parasite fitness – using the rodent malaria model, Plasmodium chabaudi chabaudi.
Results: Neutralizing interleukin [IL]-10, an important regulator of inflammation, allowed us to
experimentally increase the proportion of virulence due to immunopathology for eight parasite
clones. In vivo blockade of the IL-10 receptor (IL-10R) with a neutralizing antibody resulted in a
shorter time to death that was independent of parasite density and was particularly marked for
normally avirulent clones. This suggests that IL-10 induction may provide a pathway to avirulence
for P. c. chabaudi. Despite the increased investment in transmission-stage parasites observed for
some clones in response to IL-10R blockade, experimental enhancement of immunopathology
incurred a uniform fitness cost to all parasite clones by reducing lifetime transmission potential.
Conclusion:  This is the first experimental study to demonstrate that infection-induced
immunopathology and parasite genetic variability may together have the potential to shape
virulence evolution. In accord with recent theory, the data show that some forms of
immunopathology may select for parasites that make hosts less sick.
Background
Understanding why some pathogens are more virulent
than others is a major challenge. Medical and veterinary
science seldom look for evolutionary explanations of why
virulent pathogen strains might spread in a host popula-
tion, but recent theoretical advances suggest that an evo-
lutionary approach could provide more effective ways to
manage infectious disease [1]. Much current thinking on
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the evolution of parasite virulence, defined here as mor-
tality due to infection, is based on the parasite-centric idea
that virulence is an incidental and unavoidable conse-
quence of extracting resources from hosts in order to gen-
erate transmission opportunities. Under this view, high
levels of host exploitation enhance transmission (the fit-
ness benefit of virulence), but increase the risk of host
death (the fitness cost of virulence). This assumed associ-
ation between virulence and transmission represents an
evolutionary trade-off between how extensively parasites
replicate and the duration of the infectious period.
According to this trade-off view, parasite virulence is opti-
mized by balancing virulence and replication such that
transmission is maximized over the duration of infection
[2-6].
Most theory on the evolution of virulence is therefore
based on two key assumptions: that disease severity
increases with parasite exploitation of hosts, and that
immunity acts solely to reduce parasite titres and the
probability of death. However, biomedical literature
shows that a very significant proportion of infection-
induced disease can be immune-mediated, and even inde-
pendent of parasite replication. Indeed, many important
human infectious diseases are most lethal when associ-
ated with immune-mediated disease (immunopathol-
ogy), regardless of parasite density [7]. In malaria, for
example, the host immune response has been implicated
as the cause of many symptoms of infection [8-10] and
may help to explain the discordance that is often observed
between virulence and parasite load [11,12]. Immunolog-
ical hyperactivity has also been shown to play a role in the
pathogenesis of mucosal [13] and cutaneous leishmania-
sis [14] as well as the H5N1 [15] and, most likely, 1918
influenza viruses [16], among other infections. An unreg-
ulated immune response to infection has the potential to
cause substantial damage to host tissues.
Immune responses can thus kill both hosts and parasites.
For the most part, evolutionary theory assumes only the
latter, but even that is not always right: some immune
responses cause disease without killing parasites. For
example, in schistosomiasis, immune responses to para-
site eggs can cause serious liver disease that is unrelated to
the clearance of adult parasites [17]. Recognising this, sev-
eral authors have argued that immunopathology is a
major complication for the parasite-centric trade-off
model of virulence evolution (e.g., [7,18,19]), and the
implications of excessive immune responses for standard
models of the evolution of virulence are now beginning to
be subject to theoretical investigation (e.g., [20,21]).
Indeed, recent theoretical work has shown that immun-
opathology has the potential to alter the cost/benefit ratio
of virulence and may thus alter the trajectory of parasite
virulence evolution [20,21]. A key empirical question
which arises is how immunopathology affects parasite fit-
ness. Do parasites experience increased or decreased trans-
mission when hosts suffer immune-mediated disease?
Does the induction of immunopathology, as well as its
effect upon transmission, vary by parasite genotype? The
answers to these questions would elucidate whether and
how natural selection due to immunopathology could
shape parasite virulence.
Here, we addressed these questions in the context of
malaria, where it has been argued that the trade-off model
applies [22]. We explored the effect of immunopathology
on key fitness components of the parasite – infection-
induced mortality and lifetime transmission potential –
using the rodent malaria parasite, Plasmodium chabaudi
chabaudi. In this system, a rapid pro-inflammatory
response is essential to control rising parasitaemia, but an
overzealous induction of the same mediators is associated
with immunopathology and poor disease outcome
[23,24]. To experimentally manipulate immunopatholog-
ical virulence, we used a reagent to neutralize the activity
of Interleukin [IL]-10, a potent anti-inflammatory mole-
cule [25] which helps to prevent immune hyperactivity
during malaria infection. Previous studies using rodent
models of malaria infection have shown that ablating IL-
10 signalling promotes the development of immune-
mediated cerebral malaria [26,27] and results in lethal
inflammatory responses [28-30]. By using IL-10 receptor-
specific monoclonal antibodies (IL-10R mAb IgG, BD
PharMingen, hereafter called αIL-10R) to block in vivo IL-
10R signalling during rodent malaria infection [31], we
experimentally generated an immune-mediated increase
in host mortality rate. We then explored the genotype-spe-
cificity of this effect, as well as the consequences an
increase in immunopathological virulence may have on
the number of transmission-stage parasites (gametocytes)
produced.
Results
IL-10 receptor blockade differentially decreased time to 
death, depending on parasite genotype
IL-10R blockade significantly decreased the survival of
infected mice (Figure 1; treatment: Z = 2.02, P = 0.04, n =
80). For example, 100% of AD-infected mice died before
day 9 p.i. if IL-10 signalling was blocked, whereas only
20% of control AD mice died by day 21 (Figure 1). The
extent to which IL-10R blockade affected the time to death
depended on parasite genotype (Figure 1; clone: χ2
7, =
18.56,  P  = 0.01, treatment × clone: χ2
7, = 23.05, P  =
0.002): for example, the increase in immunopathological
virulence was greatest for the normally avirulent clones
CW or AS, which were brought to lethality (Bonferroni P
≤ 0.025 for pair-wise comparisons of the IgG versus αIL-
10R treatments for clones CW or AS; P ≥ 0.09 for all otherBMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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pair-wise comparisons of treatment effects). Thus, IL-10 R
blockade pushed normally benign infections to lethality.
Total parasite burdens did not explain the increase in 
mortality
Mice with IL-10R blockade had significantly lower total
and peak parasite densities compared to control mice
(Figure 2; treatment F1,64 = 192.9, P < 0.0001; treatment
F1,64 = 41.8, P < 0.0001, respectively). Clones differed in
total and peak parasite density, in agreement with previ-
ous work [32], but the effect of IL-10R blockade on para-
site load did not vary across clones (Figure 2; for total
parasite density, clone: F7,64 = 2.69, P = 0.017; and treat-
ment × clone: F7,64 = 1.1, P = 0.39; for peak parasite den-
sity, clone: F7,64 = 3.53, P = 0.003; and treatment × clone:
F7,64 = 1.6, P = 0.15). In addition, mortality rates decreased
with increasing peak parasite density in the IL-10R treated
group, but not in the control group (Figure 3: r = -0.34, P
= 0.01 and r = 0.22, P = 0.17, respectively). The same pat-
tern was observed for total parasite density (data not
shown). These data suggest that an uncontrolled inflam-
matory response, and not increased parasite load, caused
the increase in mortality following IL-10R blockade.
IL-10R blockade altered the transmission potential of all 
parasite genotypes
The total gametocyte density produced during infection
was significantly lower in mice with IL-10R blockade,
regardless of parasite genotype (Figure 4A and 4B; treat-
ment: F1,60 = 8.8, P = 0.004, clone: F7,60 = 3.85, P = 0.002,
treatment × clone: F7,60 = 0.47, P = 0.85). Taking day of
death into account allowed us to test statistically whether
the immune-mediated increase in mortality caused by IL-
10R blockade (see Figure 1 and day to death insets in Fig-
ure 4A) incurred a cost to the lifetime transmission poten-
tial. Statistically controlling for day to death (F1,59 = 7.14,
P = 0.01) accounted for the effects of IL-10R blockade on
lifetime transmission potential (treatment: F1,59 = 0.56, P
= 0.46, clone: F7,59 = 3.85, P = 0.002, treatment × clone:
F7,59 = 0.74, P = 0.64). Furthermore, total parasite load did
not significantly predict lifetime transmission potential
(F1,58 = 0.54, P = 0.47) and including it in the above statis-
tical models did not alter the effects of IL-10R blockade or
parasite genotype (data not shown). These data suggest
that the immune-mediated increase in mortality rate
caused by blocking IL-10R imposed a fitness cost to the
parasite in terms of decreased lifetime transmission
Effect of IL-10R blockade on the extent decreased in survival time depended on P. c. chabaudi parasite genotype Figure 1
Effect of IL-10R blockade on the extent decreased survival time depended on P. c. chabaudi parasite genotype. 
C57BL/6J mice were administered neutralizing αIL-10R mAb or control IgG, 1 day before and on days 1, 2, 3 and 4 post infec-
tion with 106 parasites of one of eight distinct P. c. chabaudi clones (CW, AS, AD, AQ, BC, AJ, AT or ER). Each pie-chart symbol 
represents the proportion of mice surviving until day 21 (white fill), while the position of the pie-chart along the y-axis indicates 
mean time to death in that treatment group (based on the mean of five mice ± S.E.). Day 21 was chosen as the end-point, to 
ensure that the acute phase of malaria infection was captured. Thus a mean of 21 without variance and with solid white fill indi-
cates no mice died from that treatment group. Relative to control mice, αIL-10R treated mice suffered a higher mortality rate 
(~15% versus ~100%, respectively) and a quicker time to death (average time to death: 18.1 +/- 0.1 versus 7.5+/-0.2 days, 
respectively) and normally avirulent P. c. chabaudi clones were brought to lethality when IL-10R was blocked.BMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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Total parasite densities were lower during IL-10R blockade, regardless of P. c. chabaudi parasite genotype Figure 2
Total parasite densities were lower during IL-10R blockade, regardless of P. c. chabaudi parasite genotype. Line 
graphs represent the dynamics of total parasite density in αIL-10R (filled symbols) or control IgG (open symbols) treated mice 
during single-clone infections with each of eight P. c. chabaudi clones. Each line represents the mean of five mice (± S.E.), except 
where deaths had occurred. Regardless of P. c. chabaudi parasite genotype, neutralizing IL-10R resulted in lower total parasite 
densities between days 3 to 21 p.i. and lower early parasite densities (days 3–8 p.i.) compared to control mice.BMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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potential regardless of parasite genotype and independent
of total parasite load. As total gametocyte density should
closely correlate with parasite fitness in this system [32-
34], these data suggest that the increase in immune-medi-
ated mortality incurred a universal cost to parasite fitness.
However, the total gametocyte density reached before day
8 post infection (total early gametocyte density) of dis-
tinct clones was differentially affected by treatment (Fig-
ure. 4C; treatment: F1,60 = 5.4, P = 0.024, clone: F7,60 = 4, P
= 0.001, treatment × clone: F7,60 = 3.3, P = 0.005). In par-
ticular, IL-10R blockade tended to increase the early trans-
mission potential of clones CW, AS or ER (Figure. 4A and
4C: Bonferroni-corrected P = 0.025, P = 0.070 and P =
0.077, respectively) but not for the remaining clones
(Bonferroni P = 0.2 for treatment within clone). These
results held even when parasite load during this early time
period was controlled for (data not shown). Thus, early in
infection (i.e., before αL-10R treatment caused death), the
effect of IL-10R blockade on gametocyte density
depended on parasite genotype; being beneficial to the
transmission potential of clones CW, AS and ER, while
not affecting the transmission potential of clones AT, AQ,
BC, AJ and AD.
Discussion
The role pathological immune responses play in shaping
the evolution of parasite virulence is an important ques-
tion that has not previously been empirically addressed.
In this study, we examined how immunopathological vir-
ulence affects the fitness of rodent malaria parasites. We
experimentally manipulated the potent anti-inflamma-
tory cytokine IL-10 [25,35], an immune signaling mole-
cule that is thought to be under balancing selection in
human populations: genetic predisposition to strong IL-
10 responses is beneficial in terms of avoiding excessive
inflammation but costly in terms of reduced ability of
hosts to control parasite replication [36]. In rodent mod-
els of infectious disease, neutralizing IL-10 leads to
uncontrolled pro-inflammatory responses and thus
increased immunopathological virulence of many para-
sites [37-39]. Indeed, the importance of IL-10 in confer-
ring protection against lethal inflammatory responses
during acute P. c. chabaudi infection with a single parasite
genotype (clone AS) is well established [27-30]. However,
the effect of overzealous immune responses on the life-
time transmission potential of genetically distinct malaria
parasites that vary in virulence has not, until now, been
examined.
Effect of IL-10R blockade on the relationship between virulence and asexual parasite density Figure 3
Effect of IL-10R blockade on the relationship between virulence and asexual parasite density. Virulence, as meas-
ured in terms of mortality rate (1/day of death), is plotted against maximum parasite density for each of 8 parasite genotypes in 
αIL-10R (filled symbols) versus IgG control (open symbols) treated mice. Pearson correlation analyses revealed a significant 
negative relationship between virulence and asexual parasite density when IL-10R was blocked, but not in control mice. This 
suggests that the αIL-10R-driven increase in mortality was caused by uncontrolled inflammatory responses, and not increases 
in parasite load. Indeed, the same pro-inflammatory molecules that kill parasites also kill hosts [29]. Each large symbol repre-
sents the mean of five mice (± S.E) and small symbols represent individual mice.BMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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The mortality caused by IL-10R blockade incurred a universal cost to lifetime transmission potential, but early in infection  clones differed in their response to IL-10R blockade Figure 4
The mortality caused by IL-10R blockade incurred a universal cost to lifetime transmission potential, but early 
in infection clones differed in their response to IL-10R blockade. (A) Line graphs compare the dynamics of gametocyte 
density during IL-10R blockade (filled symbols) or control IgG treatment (open symbols) during single-clone infections with 
each of eight P. c. chabaudi clones. Insets show day to death for each of the clones in αIL-10R (filled bars) versus IgG (open 
bars) treated mice. Bar graphs represent the least squares mean of total gametocyte density (days 4–21 p.i. inclusive, an esti-
mate of lifetime transmission potential) (B), or early gametocyte density (days 3–8 p.i. inclusive) (C), broken down by treat-
ment and P. c. chabaudi parasite clone. Each line or bar represents the mean of five mice (± S.E.), except where deaths had 
occurred. Regardless of P. c. chabaudi parasite genotype, blocking IL-10R reduced the lifetime transmission potential relative to 
control mice (A and B). However, the extent to which IL-10R blockade directly affected early gametocyte density depended on 
P. c. chabaudi parasite clone (C).BMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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We found that IL-10R blockade increased the risk of host
death, independent of the total parasite burden. Indeed,
in that treatment group, mortality rate actually increased
with decreasing parasite density (Figure 3). This result is
unsurprising because the same molecules that promote
malaria parasite clearance also cause direct harm to the
host – for example, cerebral hemorrhage and edema [27].
All infections were brought to lethality when IL-10R was
blocked, but this effect was most pronounced for the nor-
mally benign clones CW and AS, which were converted
from avirulent to killer parasites (Figure 1). It may be that
their characteristic avirulence [32] is related in part to
their induction of anti-inflammatory molecules such as
IL-10 (discussed in more detail below). We also showed
that the immunopathological acceleration of host death
imposed a universal fitness cost to the parasites, in terms
of reduced lifetime transmission potential. Early in infec-
tion, however, some genotypes generated more gameto-
cytes in IL-10R neutralized hosts. These results suggest
that immunopathological virulence has the potential to
strongly affect parasite fitness, both indirectly (via host
death) and directly (via alterations in the production or
survival of the gametocytes themselves).
The classical adaptive trade-off hypothesis posits that host
immunity may select for higher levels of virulence [40-
42]. This theory has found empirical support in both
rodent malaria and myxomatosis [43,44]. For example,
previous work on P. c. chabaudi in mice revealed that the
induction of an immune response which clears parasites
preserves positive virulence-transmission relationships
[45] and promotes the evolution of greater virulence [46].
In Australian rabbits, myxomatosis initially caused a case
fatality rate of ~99.9%, quickly evolved to intermediate
levels of virulence [47], and later become more virulent
[48]. Selection for enhanced resistance (i.e., immunologi-
cal control of the virus) has been implicated in driving
myxoma virulence upwards again [49,50]. Thus, there is
empirical support for the theory that protective immune
responses select for more virulent parasites.
However, whether the predictions of classical theory hold
in the face of pathogenic immune responses, and thus an
immune-mediated component to parasite virulence, will
depend on how immunopathology affects lifetime trans-
mission potential. Recent theoretical developments con-
firm that immunopathology is likely to alter the trajectory
of virulence evolution in certain contexts [21]. Essentially,
the mechanism by which immune-mediated disease
arises matters. For example, if immunopathology arises
independently of parasite exploitation (estimated here as
parasite density), evolution is expected to favor increased
virulence. In that case, immunopathology has the effect of
increased background mortality; regardless of what the
parasite does, the host will die, so it should aggressively
exploit its host. On the other hand, if immunopathology
increases with increased host exploitation – particularly
when the immunopathological "side effect" of exploita-
tion is greater for higher rates of immune clearance – then
parasites which more prudently exploit their hosts would
be favored. In such cases, more benign parasite strains will
spread through the host population [21]. For P. c.
chabaudi  in immunologically intact animals, we expect
immunopathology to increase with exploitation, because
autoimmune destruction of uninfected red blood cells, for
example, scales proportionally with parasite density in
this system [51]. At the same time, our empirical results
indicate that experimentally-induced increases in inflam-
mation (a likely correlate of clearance rate) increase viru-
lence (Figure 1), and that virulent parasite genotypes
induce more inflammation per parasite, in unmanipu-
lated hosts [52]. Thus, for P. c. chabaudi, the immun-
opathological side effect of exploitation may indeed be
higher for higher rates of immune clearance. Together,
these observations suggest that evolution might favor
reduced malaria virulence [21]. However, protective
immune responses against malaria impose the opposite
selection pressure [46], and the relative strengths of these
potentially conflicting effects of immunity remain to be
investigated. Regardless of the exact mechanism, it
appears that expanding the trade-off theory to incorporate
immunopathology [21] may be important for under-
standing the evolution of malaria parasites.
Differences among parasite genotypes in the extent to
which their characteristic virulence appears to depend
upon IL-10 induction are also highlighted by our results.
The panel of eight clones represents a spectrum of genetic
diversity for virulence [32]. Although clone virulence does
increase with increasing parasite densities overall [32],
there is variation about this relationship which may be
caused by differential propensity to modulate pathologi-
cal immune responses. We have previously shown that a
subset of the clones varies in per-parasite virulence as well
as the immune responses that they induce [52], as out-
lined above. Clone BC, for example, induces strong pro-
inflammatory responses and causes high virulence at rela-
tively low parasite densities, whereas the avirulent clones
AS and CW induce significantly higher plasma concentra-
tions of IL-10 and lower concentrations of pro-inflamma-
tory molecules compared to virulent clones [52]. In
support of these associations, the virulence of AS and CW
in the present study was highly sensitive to the absence of
IL-10 signalling (Figure 1), though we acknowledge that
our experimental manipulation may have maximized vir-
ulence and contributed to the lack of clone differences in
mortality rate in that treatment group.
One approach to prudent exploitation could thus include
avoidance of immunopathology via induction of anti-BMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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inflammatory factors such as IL-10. This could have a
combined benefit for parasites: impairing both protective
and pathological immune responses, thereby permitting
high parasite densities while minimizing per-parasite vir-
ulence. Many extracellular pathogens are thought to
exploit IL-10 in order to subvert host immunity and
enhance parasite survival [53]. For example, both Epstein-
Barr virus (EBV) [54] and cytomegalovirus [55] infected
cells express a viral homologue of IL-10 with similar
immunomodulatory activity to host IL-10. In addition,
induction of IL-10 allows chronic lymphocytic chori-
omeningitis infection to persist, with IL-10R blockade
resulting in viral clearance [56,57]. Immunopathology
associated with these viruses may be ameliorated by IL-10
as well. If IL-10 mediated pathways are indeed proven to
be a mechanism of avirulence during P. c. chabaudi infec-
tion, it suggests that immunomanipulation by parasites
may function to control both protective (parasite-killing)
and pathological host responses. Thus, for a given level of
exploitation, selection might favor rodent malaria para-
site genotypes that induce anti-inflammatory molecules.
Of biomedical interest, it has been suggested that the cel-
lular source of IL-10 may vary in response to infection
with different pathogens (or even genetically distinct iso-
lates of the same pathogen), the stage of infection, or ana-
tomical location [25]. It would be interesting to
investigate whether differences among P. c. chabaudi
clones in the cellular source or timing of IL-10 induction
play a role in determining the characteristic virulence
schedules we observe.
Another potential role for parasite genotype in this system
is raised by our observation that early in infection, IL-10R
blockade directly and differentially affected the gameto-
cyte load of distinct parasite genotypes (Figure 4A and
4C). The absence of IL-10 signalling was beneficial to the
short-term transmission potential of clones CW, AS and
ER but did not significantly affect clones AT, AQ, BC, AJ
and AD (Figure 4C), even when asexual parasite load was
taken into account. It is possible that the gametocytes of
different clones are differentially sensitive to being killed
by the immune system, though previous experiments
have showed no differences in sensitivity to the pro-
inflammatory molecule Tumor Necrosis Factor (TNF)-α
for a subset of the clones studied here [58]. An alternative
explanation for Figure 4C is related to the observation that
rates of gametocyte production often increase under con-
ditions which do not favour asexual replication [59-61].
For instance, the rate of gametocyte production during P.
c. chabaudi infection increases during sub-curative anti-
malarial chemotherapy [33,62]. Thus, it is possible that
changes to the immune environment caused by manipu-
lating IL-10 could trigger clones CW, AS and ER to
increase gametocyte production. Why clones might differ
in their cue for gametocytogenesis, and indeed whether
transient increases in gametocyte density in response to
excess inflammation matter evolutionarily, given the
decrease in transmission potential caused by early host
death, is unclear. The immune-mediated increase in early
gametocyte density may indeed be important in natural
populations in which hosts may suffer other sources of
mortality during an infection, thereby placing a greater
value on early gametocytogenesis. Theory [21] could pos-
sibly be extended to include cases where immunopathol-
ogy directly affects transmission (as opposed to affecting
transmission only via host death).
Conclusion
Immune responses which kill parasites can have the side
effect of killing hosts. This fact has important implications
for host defense strategies, and may have shaped the evo-
lution of the vertebrate immune system [7]. Here we have
focused our discussion on parasite evolution. In our
experiments, immunopathology reduced lifetime trans-
mission potential of parasites by reducing host life expect-
ancy. We also observed parasite genetic diversity in the
extent to which the characteristic virulence of a clone
depended upon IL-10. These observations together sug-
gest the following possibilities. Selection favors parasite
strains which effectively exploit hosts, but those strains
may inevitably induce immune-mediated disease; one can
thus imagine that selection should also favor strains able
to modify the immunopathological consequences of
infection. How the potentially conflicting selective pres-
sures imposed by protective and pathological aspects of
host immunity interact and play out will determine
whether selection favors strains which cause more or less
severe disease. In addition, our results imply that the evo-
lutionary trajectory of malaria virulence may be altered by
changes to the IL-10 milieu of a host population. A prev-
alent example in nature would be the presence of IL-10-
inducing helminths in co-infected populations [63,64].
All of these hypotheses merit further investigation – for
example, via experimental evolution of malaria para-
sites[46] in host lineages particularly prone to immun-
opathological virulence such as the αIL-10R treated hosts
in the present study, versus those particularly unlikely to
exhibit immunopathology such as hosts to whom recom-
binant IL-10 is experimentally added. Molecular-level
manipulation of parasite phenotypes (e.g., in induction of
inflammation) could also prove useful tools in studies of
experimental evolution. More generally, our results lend
support for detailed investigations of the relationship
between immunopathological virulence and transmissi-
bility in parasites of medical importance. Such studies
could elucidate the consequences of not only lethal but
also sublethal immunopathologies for parasite transmis-
sion (e.g., including the effects of fever itself [10] and/or
host debilitation [4] on transmission biology). We con-
tend that a better understanding of how host immunity –BMC Evolutionary Biology 2008, 8:128 http://www.biomedcentral.com/1471-2148/8/128
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both protective and pathological – affects parasite trans-
mission in the field would help shed light on the limits to
and causes of parasite virulence in nature.
Methods
Mice and parasites
Mice were 6–8 week old female inbred C57BL/6 mice
(bred in house). Plasmodium chabaudi chabaudi (P. c.
chabaudi: [65]) clones were derived from African thicket
rat isolates and stored as frozen stabilites [66]. Eight
clones with different virulence schedules were used [32],
with subscripts denoting their precise clonal histories;
CW706, AS12280, AD119, AQ231, BC248, AJ5166, AT89 and
ER641 (herein referred to as clones CW, AS, AD, AQ, BC,
AJ, AT and ER). P. c. chabaudi AS infection is normally
non-lethal in the strain of mice we used (C57BL/6J) [67]
and previous studies from our lab have shown a propor-
tion of sub-lethal virulence (e.g., anaemia or loss of body
mass) is immune-mediated and independent of parasite
density [52]. Mice were inoculated and housed as
described previously [52].
IL-10R blockade
IL-10 signalling can be neutralized in vivo during rodent
malaria infections by the intra peritoneal (i.p.) injection
of 20 µg of neutralizing anti-IL-10R monoclonal IgG anti-
body (clone 1B1.3a; BD PharMingen) [31]. Using this
procedure, groups of mice were injected i.p. with control
IgG (Sigma-Aldrich) or αIL-10R and, the following day,
single-clone infections were initiated as described previ-
ously, at 106 parasite dose ([52], 5 mice per P. c. chabaudi
clone or uninfected control group, per antibody treat-
ment: n = 100 mice). Antibody treatments were applied
again on days 1 to 4 post-infection inclusively. The unin-
fected but IL-10 depleted group experienced no mortality,
nor loss of red blood cell density or body mass, so IL-10R
treatment per se does not promote virulence in the absence
of infection.
Parasite density and virulence
Thin blood smears prepared from tail blood were Giemsa
stained and microscopically analysed (× 1000 magnifica-
tion) to calculate the proportion of RBCs parasitized with
gametocytes and asexual parasites. Each day post infec-
tion, RBC densities were obtained by flow cytometery
(Beckmann Coulter) by standard methods [52]. Daily
gametocyte and parasite densities (per ml blood) were cal-
culated by multiplying each corresponding proportion by
the appropriate RBC density. Time to death was recorded
until the experiment was terminated on day 21 p.i.
Trait definition
Mortality data were analysed as time to death (days). Par-
asite load was quantified as the total parasite density
reached by day 21 p.i. and, as the vast majority of deaths
occurred before day 8 (~80%), data were also analysed as
the total parasite load reached by day 8 p.i. (before the
majority of deaths occurred). Gametocyte density corre-
lates positively with infectivity to mosquitoes and, when
summed over course of infection, provides an indicator of
lifetime transmission potential [32-34]. Lifetime trans-
mission potential was quantified as the total gametocyte
density produced throughout the infection (days 3–21 p.i.
inclusive). The total gametocyte density reached before
day 8 post infection (total early gametocyte density) was
also analyzed. Four parasitized mice failed to develop
gametocytes and were not included in our analyses of
gametocyte data. Prior to statistical analysis the following
transformations were applied to meet the necessary nor-
mality and homogeneity-of-variances assumptions:
square root (gametocyte and parasite density) and 1/
square root(time to death).
Statistical analysis
All parasite and gametocyte data were analysed using
ANOVAs and ANCOVAs in Minitab (v. 14, Minitab Inc.).
Time-to-death data were analysed using Minitab's "regres-
sion with life data" command which uses a modified
Newton-Raphson algorithm to calculate maximum likeli-
hood estimates of model parameters. "Regression with life
data" accepts right censored data and a Weibull distribu-
tion was used in our models. The analysis is based upon a
Z statistic for factors with 1 degree of freedom. For predic-
tor variables with more than two levels (e.g., clone), sig-
nificance tests were based upon assessment of
improvement in model fit using a χ2 distribution. For all
analyses, explanatory variables used were antibody 'treat-
ment' (anti-IL-10R or hu-IgG), infecting P. c. chabaudi
'clone' (CW, AS, AD, AQ, BC, AJ, AT and ER) and the inter-
action between treatment and clone. To determine
whether treatment or clone had effects on time to death
and gametocytes beyond those exerted via total parasite
load, data were analysed with and without total parasite
load as a covariate. The maximal model was first fit to the
data including treatment, clone, an interaction between
treatment and clone, and covariate when relevant. Models
were minimized by removing non-significant terms (P >
0.05), beginning with the interaction. The relationship
between mortality rate (1/day of death) and asexual para-
site density was analysed for all mice within a treatment
using Pearson's correlation coefficient.
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